The latest price target for Achilles Therapeutics (NASDAQ:ACHL) was reported by Piper Sandler on April 5, 2024. The analyst firm set a price target for $2.00 expecting ACHL to rise to within 12 months (a possible 104.08% upside). 2 analyst firms have reported ratings in the last year.

The latest analyst rating for Achilles Therapeutics (NASDAQ:ACHL) was provided by Piper Sandler, and Achilles Therapeutics downgraded their neutral rating.

There is no last upgrade for Achilles Therapeutics

The last downgrade for Achilles Therapeutics PLC happened on April 5, 2024 when Piper Sandler changed their price target from $8 to $2 for Achilles Therapeutics PLC.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Achilles Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Achilles Therapeutics was filed on April 5, 2024 so you should expect the next rating to be made available sometime around April 5, 2025.

While ratings are subjective and will change, the latest Achilles Therapeutics (ACHL) rating was a downgraded with a price target of $8.00 to $2.00. The current price Achilles Therapeutics (ACHL) is trading at is $0.98, which is out of the analyst’s predicted range.